{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:30:05Z","timestamp":1793608205375,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,30]],"date-time":"2027-07-30T00:00:00Z","timestamp":1816905600000},"content-version":"am","delay-in-days":394,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.02.013","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:36:29Z","timestamp":1771997789000},"page":"745-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical, functional and therapeutic evaluation of CFTR variant I507del"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-3714","authenticated-orcid":false,"given":"Neeraj","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Starego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5405-9401","authenticated-orcid":false,"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Kleist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2584-8821","authenticated-orcid":false,"given":"Madison","family":"Havens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7501-9480","authenticated-orcid":false,"given":"Jalloh S.","family":"Neneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alianna","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"Clement L.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Vanscoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6854","authenticated-orcid":false,"given":"Karen S.","family":"Raraigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Merlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5533-9130","authenticated-orcid":false,"given":"David N.","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-8590","authenticated-orcid":false,"given":"Garry R.","family":"Cutting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2026.02.013_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"issue":"10","key":"10.1016\/j.jcf.2026.02.013_bib0002","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ng.2745","article-title":"Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene","volume":"45","author":"Sosnay","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.013_bib0003","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.013_bib0004","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"10.1016\/j.jcf.2026.02.013_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2026.02.013_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jcf.2026.02.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121159","article-title":"Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators","volume":"3","author":"Han","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.jcf.2026.02.013_bib0008","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.013_bib0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jcf.2025.02.008","article-title":"Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers","volume":"24","author":"Conti","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.02.013_bib0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cbic.201500620","article-title":"Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis","volume":"17","author":"Lopes-Pacheco","year":"2016","journal-title":"Chembiochem"},{"key":"10.1016\/j.jcf.2026.02.013_bib0011","article-title":"Personalized medicine in cystic fibrosis: characterization of eight rare CFTR variants in intestinal organoids and cellular models","author":"Railean","year":"2025","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcf.2026.02.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.013_bib0013","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1165\/rcmb.2023-0398OC","article-title":"Investigation of CFTR function in human nasal epithelial cells informs personalized medicine","volume":"71","author":"Pion","year":"2024","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2026.02.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2523950123","article-title":"Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant","volume":"123","author":"Rodrat","year":"2026","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.jcf.2026.02.013_bib0015","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1074\/jbc.M116.751537","article-title":"Two small molecules restore stability to a subpopulation of the cystic fibrosis transmembrane conductance regulator with the predominant disease-causing mutation","volume":"292","author":"Meng","year":"2017","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jcf.2026.02.013_bib0016","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.ajhg.2018.04.003","article-title":"Functional assays are essential for interpretation of missense variants associated with variable expressivity","volume":"102","author":"Raraigh","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.jcf.2026.02.013_bib0017","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcf.2022.02.001","article-title":"How the sweat gland reveals levels of CFTR activity","volume":"21","author":"Wine","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"9","key":"10.1016\/j.jcf.2026.02.013_bib0018","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jcf.2026.02.013_bib0019","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jcf.2024.09.004","article-title":"Calibrating sweat chloride levels to CFTR activity via ETI effects on CF subjects with one or two F508DEL mutations","volume":"23","author":"Wine","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2026.02.013_bib0020","first-page":"1178","article-title":"Genetic determination of exocrine pancreatic function in cystic fibrosis","volume":"50","author":"Kristidis","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1016\/j.jcf.2026.02.013_bib0021","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S2213-2600(24)00205-4","article-title":"Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTR(N1303K) in the USA: a prospective, multicentre, open-label, single-arm trial","volume":"12","author":"Solomon","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"6617","key":"10.1016\/j.jcf.2026.02.013_bib0022","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of Delta508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.013_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47020119","article-title":"Unraveling the mechanism of action, binding sites, and therapeutic advances of CFTR modulators: a narrative review","volume":"47","author":"Baroni","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.013_bib0024","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"18","key":"10.1016\/j.jcf.2026.02.013_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810956","article-title":"The CFTR amplifier nesolicaftor rescues TGF-beta1 inhibition of modulator-corrected F508del CFTR function","volume":"23","author":"Bengtson","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.jcf.2026.02.013_bib0026","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1111\/bph.12791","article-title":"CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR","volume":"171","author":"Wang","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.jcf.2026.02.013_bib0027","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/bph.15709","article-title":"A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR","volume":"179","author":"Liu","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2026.02.013_bib0028","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1113\/JP285727","article-title":"Two rare variants that affect the same amino acid in CFTR have distinct responses to ivacaftor","volume":"602","author":"Li","year":"2024","journal-title":"J Physiol"},{"issue":"5","key":"10.1016\/j.jcf.2026.02.013_bib0029","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:14:01Z","timestamp":1793607241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1569199326000421"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical, functional and therapeutic evaluation of CFTR variant I507del","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}